TrialRespiratory research2020

Navafenterol (AZD8871) in patients with COPD: a randomized, double-blind, phase I study evaluating safety and pharmacodynamics of single doses of this novel, inhaled, long-acting, dual-pharmacology bronchodilator.

Dave Singh et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.